Your Pharmacy May Not Exist: Verifying Who Actually Made Your Medication
The FDA has warned that some compounded GLP-1 products carry false label information — including pharmacy names that do not exist or did not make the drug. Here is how to check.
The short version
- The FDA has warned that some compounded semaglutide and tirzepatide products carry false label information, including pharmacy names that either do not exist or did not make the drugs.
- A telehealth brand is usually not the pharmacy. The name on the box and the name on the vial are frequently different entities.
- State board of pharmacy licence lookups are free, public, and take about five minutes.
- If the vial has no pharmacy name, no lot number, and no beyond-use date, stop and call your prescriber.
Most people never look at who made their medication, and for FDA-approved drugs that instinct is reasonable — the supply chain is registered and inspected end to end. Compounded products are different, and the FDA has said so directly: some compounded semaglutide and tirzepatide products carry false label information, including pharmacy names that either do not exist or did not make the drugs.
The three-entity problem
When you buy compounded semaglutide through a telehealth site, you are typically dealing with at least three separate businesses:
- The brand you signed up with. This is a marketing and subscription company. It is almost never a pharmacy.
- The clinician network. Often a separate contracted entity supplying licensed prescribers. Reporting on the sector has traced several telehealth brands back to shared clinician networks such as OpenLoop, whose marketing states it provides vetted and credentialed clinicians for its telehealth network.
- The compounding pharmacy. A fourth party you may never be told about until the box arrives — and sometimes not even then.
None of this is inherently improper. It becomes a problem when the arrangement is opaque enough that you cannot identify who is accountable for what is in the vial.
A legitimately dispensed compounded preparation should identify the compounding pharmacy, a lot or batch number, a beyond-use date, the active ingredient and its concentration, and every added ingredient. Missing any of these is a reason to stop and ask questions before you inject.
How to verify, in about five minutes
1. Find the pharmacy name
Look at the vial label and the dispensing paperwork, not the shipping box. The telehealth brand's name on the outer packaging tells you nothing about who compounded the drug.
2. Look it up with the state board of pharmacy
Every state maintains a public licence verification database. Search the pharmacy name in the state listed on the label. You are checking three things: that the entity exists, that its licence is active, and that any disciplinary history is visible.
3. Check the FDA's registered outsourcing facility list
If the pharmacy claims to be a 503B outsourcing facility, that is a federal registration and the FDA publishes the list. A 503B claim from a facility not on that list is a significant problem.
4. Search the FDA warning letter database
Warning letters are public. Search the pharmacy name. As one example of what turns up, the FDA issued a warning letter to 503A pharmacy Boothwyn Pharmacy on January 16, 2026, published the following month, citing violations concerning insanitary conditions and noncompliance with the strength, quality, or purity of the compounded products' stated contents.
5. Ask for a certificate of analysis
Request the certificate of analysis for your specific lot. A pharmacy with functioning quality systems can produce this. Refusal, or a vague answer about proprietary information, is informative.
Providers who disclose their dispensing pharmacy
Every provider below is a paid partner. Pricing changes frequently — confirm current cost on the provider's own page before you enrol.
Semaglutide injection through a licensed US telehealth network. Injectable only — no oral formulation offered.
See Embody pricing Paid partner linkMarketplace for cash-pay appointments with clinicians who prescribe FDA-approved brand-name medication only — Rybelsus, the oral Wegovy pill, and Foundayo. No compounded product.
See Sesame Care pricing Paid partner linkTelehealth intake with both injectable and oral pathways in the questionnaire flow.
See Care Bare Rx pricing Paid partner linkRed flags that should stop the transaction
- No pharmacy name anywhere on the vial or paperwork
- A pharmacy name that returns no results in any state licence database
- No lot number or no beyond-use date
- Product shipped from outside the United States
- Labelling in a language inconsistent with the stated origin
- A provider that will not tell you which pharmacy fills your prescription, before or after you order
- Product described as research use only or not for human consumption
Sector reporting has documented complaints beyond the product itself. Customers of some telehealth weight loss services have described poorly disclosed charges, recurring subscriptions, and obstructed cancellations — including one contributor who disputed an $866 charge after registering simply to check the price of compounded tirzepatide. Read the subscription terms before you enter payment details.
What to do if verification fails
Do not use the product. Contact your prescriber, keep the vial and all packaging, and report it to the FDA's MedWatch program and to your state board of pharmacy. If you were billed for something that cannot be verified, that is also a chargeback matter with your card issuer.
Verification is a five-minute exercise that most patients skip. In a market where the FDA has explicitly warned about labels naming pharmacies that do not exist, five minutes is a reasonable investment.
Sources
- FDA warnings regarding false label information on compounded semaglutide and tirzepatide products.
- FDA warning letter to Boothwyn Pharmacy, LLC, issued January 16, 2026, published February 10, 2026.
- Pharmacy Times reporting on FDA compounding enforcement and warning letters.
- Drug Discovery Trends reporting on telehealth clinician networks and consumer billing complaints in the GLP-1 sector.
- FDA registered outsourcing facility list and MedWatch reporting program.